[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606563":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":39,"centralContacts":43,"locations":50,"responsibleParty":85,"collaborators":30,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":30,"enrollmentInfo":96,"targetDuration":30,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":53,"whyStopped":30,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"University Hospital Ostrava","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1 (control group)","ACTIVE_COMPARATOR","Patients with normal baseline serum creatinine value will be enrolled in this group. The care provided to patients in this group will not differ from the usual care provided to other patients.",[13],"Other: No intervention",{"label":15,"type":16,"description":17,"interventionNames":18},"Group 2 (intervention group)","EXPERIMENTAL","Patients with subnormal baseline serum creatinine value will be randomly assigned to group 2 or 3. One group will receive creatine as a dietary supplement and the other will receive placebo. Other care provided to subjects in these groups will not differ from the usual care.",[19],"Dietary Supplement: Dietary supplement creatine",{"label":21,"type":16,"description":17,"interventionNames":22},"Group 3 (intervention group)",[23],"Dietary Supplement: Dietary supplement - placebo",[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DIETARY_SUPPLEMENT","Dietary supplement creatine","Dietary supplement creatine. The dosage of creatine will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.",[15],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Dietary supplement - placebo","Dietary supplement polydextrose as a placebo. The dosage of placebo will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.",[21],{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"No intervention","Patients in Group 1 will serve as controls and will receive no intervention, only standard care.",[9],[40],{"name":41,"affiliation":5,"role":42},"Roman Kula, MD, CSc","STUDY_CHAIR",[44],{"name":45,"role":46,"phone":47,"phoneExt":48,"email":49},"Jiří Hynčica","CONTACT","0042059737","2587","jiri.hyncica@fno.cz",[51,70],{"facility":52,"status":53,"city":54,"state":30,"zip":55,"country":56,"countryCode":30,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Chronicare Mund s.r.o.","RECRUITING","Brno","621 00","Czechia",{"type":58,"coordinates":59},"Point",[60,61],16.60796,49.19522,{"lat":61,"lon":60},[64,68],{"name":65,"role":46,"phone":66,"phoneExt":30,"email":67},"Petr Jelínek, MD, Ph.D.","00420775530275","brno@chronicare.cz",{"name":65,"role":69,"phone":30,"phoneExt":30,"email":30},"PRINCIPAL_INVESTIGATOR",{"facility":71,"status":53,"city":72,"state":30,"zip":73,"country":56,"countryCode":30,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Chronicare s.r.o.","Milovice","289 24",{"type":58,"coordinates":75},[76,77],14.88863,50.22596,{"lat":77,"lon":76},[80,84],{"name":81,"role":46,"phone":82,"phoneExt":30,"email":83},"Anton Baluch, MD","00420326550688","milovice@chronicare.cz",{"name":81,"role":69,"phone":30,"phoneExt":30,"email":30},{"type":86,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100606563","low-serum-creatinine-as-a-predictor-of-prolonged-mechanical-ventilation-and-weaning-failure-100606563",false,"NCT07177183","Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure","SECRET-VENT","Inclusion Criteria:\n\n* Patients \\\u003C18 years of age\n* Patients admitted to post-ICU care units at Chronicare Group a.s. in the Czech Republic within 12 months\n\nExclusion Criteria:\n\n* Patients who are unlikely to be weaned from ventilatory support.\n* Patients in palliative care or with a survival probability of \\\u003C3 months\n* Patients with advanced malignancy\n* Patients with a history of chronic kidney disease\n* Patients with a history of chronic liver disease\n* Patients with supranormal serum creatinine on admission to the post-ICU care unit\n* Patients who refused to sign the Informed Consent with participation in the study.","ALL","18 Years",{"count":97,"type":98},492,"ESTIMATED","INTERVENTIONAL",[101],"NA","The main objective of the study is to determine whether a subnormal serum creatinine value upon admission to the Post-ICU Care Unit predicts the need for prolonged ventilatory support. A parallel objective of the study is to determine whether exogenous in-take of the dietary supplement creatine in patients with subnormal serum creatinine value is associated with a shortened duration of ventilatory support and improved patients outcome.",[104,105],"Prolonged Mechanical Ventilation","Critical Illness",[107,108,109,110],"Prolonged mechanical ventilation","Critical illness","Creatinine","Creatine supplementation","2026-02-02",{"date":113,"type":114},"2026-02-05","ACTUAL",{"date":111,"type":98},{"date":117,"type":98},"2028-02-02",{"name":5,"class":6},2]